Brendan Hagerty

MD
Surgical Oncology

About Brendan Hagerty

Positions

Roswell Park Comprehensive Cancer Center

  • Complex General Surgical Oncology Fellow
  • Department of Surgical Oncology

Background

Education and Training:

  • 2011-2015 - MD - Lewis Katz School of Medicine at Temple University, Philadelphia, PA

Residency:

  • 2020-2022 - Allegheny Health Network
  • 2018-2020 - National Cancer Institute Research Fellowship
  • 2015-2018 - Allegheny Health Network

Publications

Aversa JG, Diggs LP, Hagerty BL, Dominguez DA, Wiemken T, Luu C, Hernandez JM. The Impact of Level I Evidence on Multi-disciplinary Cancer Care Across the US: The CROSS Trial. JAMA Oncol. 2020;6(8):1290-1292

Hagerty BL, Pegna G, Xu J, Tai C, Alewine C. Mesothelin-targeted Immunotoxins for Solid Tumors. Biomolecules. 2020;10(7):973

Hagerty BL, Torres M, Drake J, Mullinax J, Hernandez JM, Blakely AM, Davis JL. Trends and Predictors of Failure of Minimally Invasive Surgery for Gastric GIST. J Gastrointest Surg. 2021;25:1319-1322

Hagerty BL, O’Sullivan TN, Zhang X, Collins NK, Lawrence WC, Pate N, Xu J, Guerin T, Kozlov S, Alewine C. Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. Mol Cancer Ther. 2021;20(10):2082-2092

Hagerty BL, Aversa JA, Dominguez DA, Davis JL, Hernandez JM, McCormick JT, Blakely AM. Age Determines Adjuvant Chemotherapy Use in Resected Stage II Colon Cancer. Dis Colon Rectum. 2022;65(10):1206-1214